Morgan Stanley Forecasts Strong Price Appreciation for Eli Lilly and Company (NYSE:LLY) Stock

Key Points

• Morgan Stanley raised its price target on Eli Lilly to $1,327 and maintained an "overweight" rating, implying about a 41.32% upside from the stock's current price.
• Eli Lilly posted strong results (Q: $7.54 EPS vs. $7.48 expected; revenue $19.29B, +42.6% YoY) and set FY2026 guidance of 33.50–35.00 EPS, underpinning bullish analyst expectations.
• Commercial catalysts like the Foundayo launch, Amazon Pharmacy distribution and telehealth/retail partnerships could boost uptake, but cheaper generics in India and competitive pricing from rivals (e.g., Novo Nordisk) pose share and pricing risks.

Eli Lilly and Company (NYSE:LLY - Get Free Report) had its price target increased by research analysts at Morgan Stanley from $1,313.00 to $1,327.00 in a report issued on Friday,Benzinga reports. The brokerage presently has an "overweight" rating on the stock. Morgan Stanley's price objective suggests a potential upside of 41.32% from the stock's current price.

A number of other brokerages also recently issued reports on LLY. BMO Capital Markets reissued an "outperform" rating and set a $1,300.00 price target on shares of Eli Lilly and Company in a research report on Thursday, February 5th. Berenberg Bank increased their price target on Eli Lilly and Company from $950.00 to $1,050.00 and gave the stock a "hold" rating in a research report on Thursday, February 19th. Wells Fargo & Company raised their target price on shares of Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the company an "overweight" rating in a report on Thursday, February 5th. Loop Capital set a $1,200.00 target price on shares of Eli Lilly and Company in a report on Tuesday, February 10th. Finally, Royal Bank Of Canada assumed coverage on shares of Eli Lilly and Company in a report on Tuesday, February 24th. They issued an "outperform" rating and a $1,250.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $1,224.59.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock traded down $16.18 during trading on Friday, reaching $939.01. The company's stock had a trading volume of 577,223 shares, compared to its average volume of 3,117,804. The business's 50-day moving average price is $985.96 and its 200-day moving average price is $972.98. The firm has a market cap of $887.20 billion, a PE ratio of 40.88, a P/E/G ratio of 1.11 and a beta of 0.51. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $7.48 by $0.06. The company had revenue of $19.29 billion during the quarter, compared to analysts' expectations of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. Eli Lilly and Company's quarterly revenue was up 42.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Hedge Funds Weigh In On Eli Lilly and Company

Institutional investors have recently modified their holdings of the business. 10Elms LLP lifted its stake in Eli Lilly and Company by 33.3% in the 3rd quarter. 10Elms LLP now owns 40 shares of the company's stock valued at $31,000 after purchasing an additional 10 shares during the last quarter. M.E. Allison & CO. Inc. lifted its stake in Eli Lilly and Company by 0.7% in the 4th quarter. M.E. Allison & CO. Inc. now owns 1,477 shares of the company's stock valued at $1,587,000 after purchasing an additional 10 shares during the last quarter. Tanager Wealth Management LLP lifted its stake in Eli Lilly and Company by 2.6% in the 4th quarter. Tanager Wealth Management LLP now owns 395 shares of the company's stock valued at $424,000 after purchasing an additional 10 shares during the last quarter. Morey & Quinn Wealth Partners LLC lifted its stake in Eli Lilly and Company by 1.5% in the 4th quarter. Morey & Quinn Wealth Partners LLC now owns 661 shares of the company's stock valued at $710,000 after purchasing an additional 10 shares during the last quarter. Finally, Wealthspan Partners LLC lifted its stake in Eli Lilly and Company by 0.5% in the 4th quarter. Wealthspan Partners LLC now owns 2,110 shares of the company's stock valued at $2,268,000 after purchasing an additional 10 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Foundayo U.S. launch via LillyDirect and telehealth expands prescription access and recurring revenue potential; company pricing includes low copay access ($25/month with coverage) and a self‑pay option. Foundayo press release
• Positive Sentiment: Amazon Pharmacy will stock Foundayo at kiosks and offer same‑day delivery, materially improving patient convenience and speed-to-fill — a distribution boost that can accelerate uptake. Reuters
• Positive Sentiment: Multiple retail/telehealth partnerships (WeightWatchers, GoodRx, Ro and others) expand channels, same/next‑day delivery and bundled weight‑management services that support broader commercial adoption. Yahoo Finance
• Positive Sentiment: Some Wall Street shops remain constructive ahead of Q1 results (e.g., Guggenheim bullish commentary), which can support sentiment if guidance/metrics remain strong. MSN/Guggenheim
• Neutral Sentiment: Rothschild & Co Redburn nudged its price target to $880 but kept a "neutral" rating — a small PT raise but no upgrade, leaving expectations mixed. MarketScreener
• Negative Sentiment: Cheaper generic GLP‑1/semaglutide copies in India are eroding Lilly’s early share (Lilly’s share fell from ~61% to ~56% month-to-month), showing vulnerability where price matters most. CNBC
• Negative Sentiment: Competitive moves (Novo Nordisk’s lower‑priced/higher‑dose Wegovy positioning) and broader pricing pressure could limit margin/pricing power in key markets as oral and injectable GLP‑1 options proliferate. Yahoo Finance on Novo

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.